Mandi Murph, Ph.D.
Pharmaceutical and Biomedical Sciences
|Ph.D. Biology||Georgia Institute of Technology||Atlanta, GA||2005|
|B.S. Biology||Emory University||Atlanta, GA||1999|
- Post-doctoral Experience
- Postdoctoral Fellow, M.D. Anderson Cancer Center, Houston, TX, 2005–2008
- Honors and Awards
- Suddath Award winner for pre-doctoral scientific achievement in Science and Engineering at Georgia Tech (2003)
- Research Interests
- Research interests in the laboratory include understanding the molecular biology of lysophosphatidic acid (LPA) signaling and the molecular mechanisms of drugs targeting this pathway. Various inhibitory compounds are at multiple stages of development in both academia and industry to target aberrant LPA signaling in disease. Those entering pre-clinical and clinical trials need to have a full investigation of molecular targets to predict off-target side effects of the drugs to ensure safety and FDA approval. In addition, selecting appropriate patients for clinical trial enrollment is crucial to the success of these compounds as drugs such as Tratuzumab owe their successful approval to a careful selection process. It is the long-term goal of the laboratory to contribute to the safe development of LPA signaling inhibitors that will provide much needed therapeutics to patients.
- Representative Publications
- Liu S., Murph M., Panupinthu N. and Mills, G.B. (2009) ATX-LPA receptor axis in inflammation and cancer. Cell Cycle. Nov 15;8(22):3695-701. PMID: 19855166
Liu S., Umezu-Goto M., Murph M., Lu Y., Liu W., Zhang F., Yu S., Stephens L.C., Cui X., Murrow G., Coombes K., Muller W., Hung M.C., Perou C.M., Lee A.V., Fang X., Mills G.B. (2009) Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. Jun 2;15(6):539-50. PMID: 19477432
Murph M.M., Liu W., Yu S., Lu Y., Hall H., Hennessy B.T., Lahad J., Schaner M., Helland A., Kristensen G., Børresen-Dale A.L. and Mills G.B. (2009) Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS ONE. 4(5):e5583. PMID: 19440550
Murph M.M., Smith, D.L., Hennessy, B., Lu, Y., Joy, C., Coombes, K.R., Mills, G.B. (2008) Individualized Molecular Medicine: Linking Functional Proteomics to Select Therapeutics Targeting the PI3K Pathway for Specific Patients. Adv Exp Med Biol;622:183-95. PMID: 18546628
Hennessy, B.T., Murph, M., Nanjundan, M., Auersperg, N., Almeida, J., Coombes, K., Liu, J., Lu, Y., Gray, J.W., Mills, G.B. (2008) Ovarian cancer: linking genomics to new targeted discovery and molecular markers – the way ahead. Adv Exp Med Biol;617:23-40. PMID: 18497028